Neurology

1 Items

All Items

Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy

Roberto Bergamaschi, Marco Capobianco , Roberto Ravasio

48-56

DOI: https://doi.org/10.33393/ao.2024.3078